This website uses own and third-party cookies to enhance the user's experience.
By clicking "Accept" on this banner or using our site, you consent to the use of cookies.
For settings and more information about cookies, view our
Cookie Policy.

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 9 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.

Since the announcement as of 2 September 2019, the following transactions have been made:

Number ofB shares

Averagepurchase price

Transactionvalue, DKK

Accumulated, last announcement

2,054,000

712,638,600

2 September 2019

125,000

356.79

44,598,316

3 September 2019

125,000

360.29

45,036,143

4 September 2019

120,000

363.12

43,574,297

5 September 2019

130,000

359.40

46,722,098

6 September 2019

120,000

356.60

42,792,518

Accumulated under the programme

2,674,000

935,361,972

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 33,234,044 B shares of DKK 0.20, corresponding to 1.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 6 September 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 26,075,012 B shares at an average share price of DKK 328.68 per B share equal to a transaction value of DKK 8,570,315,427.

About BiotechgateThe Swiss Life Sciences Database is a product of Venture Valuation and part of the global Life Sciences lead generation and intelligence platform Biotechgate. Our mission is to provide up-to-date company and business information of the Biotech, Pharma and Medtech sectors to professionals everywhere, in order to support them in identifying the most appropriate business partners, customers and suppliers.